Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Canadian Journal of Physiology and Pharmacology
|
September 12, 2008
Forefronts in endothelin
Pedro D'Orleans-Juste, Donald Kohan, Ariela Benigni
Lancet (London, England)
|
November 9, 2024
Sparsentan and kidney protection: improved medullary oxygenation? - Authors' reply
Donald Kohan, Jula Inrig, Brad H Rovin, et al.
American Journal of Physiology. Renal Physiology
|
December 1, 2012
Reduced ENaC activity and blood pressure in mice with genetic knockout of the insulin receptor in the renal collecting duct
Lijun Li, R Mayuri Garikepati, Susanna Tsukerman, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 4, 2015
Thromboxane prostanoid receptors enhance contractions, endothelin-1, and oxidative stress in microvessels from mice with chronic kidney disease
Cheng Wang, Zaiming Luo, Donald Kohan, et al.
Hypertension (Dallas, Tex. : 1979)
|
May 4, 2016
Impact of Angiotensin Type 1A Receptors in Principal Cells of the Collecting Duct on Blood Pressure and Hypertension
Daian Chen, Johannes Stegbauer, Matthew A Sparks, et al.
Nature Cell Biology
|
January 30, 2023
Progenitor-derived endothelin controls dermal sheath contraction for hair follicle regression
Pieter Martino, Raghava Sunkara, Nicholas Heitman, et al.
Journal of the American Society of Nephrology : JASN
|
September 23, 2021
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial
Hiddo J L Heerspink, Di Xie, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Journal of the American Society of Nephrology : JASN
|
April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy
Dick de Zeeuw, Blai Coll, Dennis Andress, et al.
Diabetes, Obesity & Metabolism
|
February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Canadian Journal of Physiology and Pharmacology
|
September 12, 2008
Forefronts in endothelin
Pedro D'Orleans-Juste, Donald Kohan, Ariela Benigni
Lancet (London, England)
|
November 9, 2024
Sparsentan and kidney protection: improved medullary oxygenation? - Authors' reply
Donald Kohan, Jula Inrig, Brad H Rovin, et al.
American Journal of Physiology. Renal Physiology
|
December 1, 2012
Reduced ENaC activity and blood pressure in mice with genetic knockout of the insulin receptor in the renal collecting duct
Lijun Li, R Mayuri Garikepati, Susanna Tsukerman, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 4, 2015
Thromboxane prostanoid receptors enhance contractions, endothelin-1, and oxidative stress in microvessels from mice with chronic kidney disease
Cheng Wang, Zaiming Luo, Donald Kohan, et al.
Hypertension (Dallas, Tex. : 1979)
|
May 4, 2016
Impact of Angiotensin Type 1A Receptors in Principal Cells of the Collecting Duct on Blood Pressure and Hypertension
Daian Chen, Johannes Stegbauer, Matthew A Sparks, et al.
Nature Cell Biology
|
January 30, 2023
Progenitor-derived endothelin controls dermal sheath contraction for hair follicle regression
Pieter Martino, Raghava Sunkara, Nicholas Heitman, et al.
Journal of the American Society of Nephrology : JASN
|
September 23, 2021
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial
Hiddo J L Heerspink, Di Xie, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Journal of the American Society of Nephrology : JASN
|
April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy
Dick de Zeeuw, Blai Coll, Dennis Andress, et al.
Diabetes, Obesity & Metabolism
|
February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Page
of 2